David Tuveson

David Tuveson

Roy J. Zuckerberg Professor of Cancer Research
Cancer Center Director

M.D., Ph.D., Johns Hopkins University, 1994

dtuveson@cshl.edu | 516-367-5246

Tuveson Lab Website   Faculty Profile

Pancreatic cancer is an extremely lethal malignancy. On average, patients who are diagnosed with pancreatic cancer succumb to the disease within 6 months. Research is the only way to defeat pancreatic cancer. My lab is making progress toward finding a cure by detecting the disease earlier and designing novel therapeutic approaches.

David Tuveson’s laboratory uses murine and human models of pancreatic cancer to explore the fundamental biology of malignancy and thereby identify new diagnostic and treatment strategies. The lab’s approaches run the gamut from designing new model systems of disease to developing new therapeutic and diagnostic approaches for rapid evaluation in preclinical and clinical settings. The lab’s studies make use of organoid cultures—three-dimensional cultures of normal or cancerous epithelia—as ex vivo models to probe cancer biology. Current projects in the lab explore changes in redox metabolism associated with pancreatic cancer tumorigenesis, dissect signaling by the Ras oncogene, discover new biomarkers of early pancreas cancer, and identify mechanisms of cross-talk between pancreatic cancer cells and the tumor stroma. Novel treatment approaches suggested by these studies are then tested by performing therapeutic experiments in mouse models. To dissect molecular changes associated with pancreatic tumorigenesis, the Tuveson lab has generated a large collection of human patient-derived organoid models. By measuring the therapeutic sensitivities of patient-derived organoids, the lab is working to identify novel strategies to treat patients as well as markers of therapeutic response. The Tuveson Laboratory maintains strong links to clinical research, and the ultimate goal is confirmation of preclinical findings in early-phase trials. Collectively, the lab’s bench-to-bedside approach is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.

Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation.

See all Tuveson news

Selected Publications

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.

7 Jun 2021 | Nature Communications | 12(1):3414
Nielsen, Sebastian, Strøbech, Jan, Horton, Edward, Jackstadt, Rene, Laitala, Anu, Bravo, Marina, Maltese, Giorgia, Jensen, Adina, Reuten, Raphael, Rafaeva, Maria, Karim, Saadia, Hwang, Chang-Il, Arnes, Luis, Tuveson, David, Sansom, Owen, Morton, Jennifer, Erler, Janine

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.

25 May 2021 | Proceedings of the National Academy of Sciences of USA | 118(21):e2016904118
Cheng, Derek, Oni, Tobiloba, Thalappillil, Jennifer, Park, Youngkyu, Ting, Hsiu-Chi, Alagesan, Brinda, Prasad, Nadia, Addison, Kenneth, Rivera, Keith, Pappin, Darryl, Van Aelst, Linda, Tuveson, David

Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer.

1 Apr 2021 | Clinical Cancer Research | 27(7):2023-2037
Steele, Nina, Biffi, Giulia, Kemp, Samantha, Zhang, Yaqing, Drouillard, Donovan, Syu, LiJyun, Hao, Yuan, Oni, Tobiloba, Brosnan, Erin, Elyada, Ela, Doshi, Abhishek, Hansma, Christa, Espinoza, Carlos, Abbas, Ahmed, The, Stephanie, Irizarry-Negron, Valerie, Halbrook, Christopher, Franks, Nicole, Hoffman, Megan, Brown, Kristee, Carpenter, Eileen, Nwosu, Zeribe, Johnson, Craig, Lima, Fatima, Anderson, Michelle, Park, Youngkyu, Crawford, Howard, Lyssiotis, Costas, Frankel, Timothy, Rao, Arvind, Bednar, Filip, Dlugosz, Andrzej, Preall, Jonathan, Tuveson, David, Allen, Benjamin, Pasca di Magliano, Marina

Fighting the Sixth Decade of the Cancer War with Better Cancer Models.

Apr 2021 | Cancer Discovery | 11(4):801-804
Tuveson, David

Diversity and Biology of Cancer-Associated Fibroblasts.

1 Jan 2021 | Physiological Reviews | 101(1):147-176
Biffi, Giulia, Tuveson, David

All Publications

Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response

1 Apr 2022 | Clinical Cancer Research
Seppälä, Toni, Zimmerman, Jacquelyn, Suri, Reecha, Zlomke, Haley, Ivey, Gabriel, Szabolcs, Annamaria, Shubert, Christopher, Cameron, John, Burns, William, Lafaro, Kelly, He, Jin, Wolfgang, Christopher, Zou, Ying, Zheng, Lei, Tuveson, David, Eshlemann, James, Ryan, David, Kimmelman, Alec, Hong, Theodore, Ting, David, Jaffee, Elizabeth, Burkhart, Richard

Lead Identification using 3D Models of Pancreatic Cancer: Development of 3D Tumor Models for High-throughput Screening.

16 Mar 2022 | Slas Discovery
Fernandez-Vega, Virneliz, Hou, Shurong, Plenker, Dennis, Tiriac, Hervé, Baillargeon, Pierre, Shumate, Justin, Scampavia, Louis, Seldin, Jan, Souza, Glauco, Tuveson, David, Spicer, Timothy

Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics

18 Feb 2022 | Cancer Research
Bhatia, Sonam, Kramer, Melissa, Russo, Suzanne, Naik, Payal, Arun, Gayatri, Brophy, Kyle, Andrews, Peter, Fan, Cheng, Perou, Charles, Preall, Jonathan, Ha, Taehoon, Plenker, Dennis, Tuveson, David, Rishi, Arvind, Wilkinson, John, McCombie, W, Kostroff, Karen, Spector, David

Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial

10 Feb 2022 | Gut
Brennan, Christina, Nadella, Sandeep, Zhao, Xiang, Dima, Richard, Jordan-Martin, Nicole, Demestichas, Breanna, Kleeman, Sam, Ferrer, Miriam, von Gablenz, Eva, Mourikis, Nicholas, Rubin, Michael, Adnani, Harsha, Lee, Hassal, Ha, Taehoon, Prum, Soma, Schleicher, Cheryl, Fox, Sharon, Ryan, Michael, Pili, Christina, Goldberg, Gary, Crawford, James, Goodwin, Sara, Zhang, Xiaoyue, Preall, Jonathan, Costa, Ana, Conigliaro, Joseph, Masci, Joseph, Yang, Jie, Tuveson, David, Tracey, Kevin, Janowitz, Tobias

Accurate and robust inference of genetic ancestry from cancer-derived molecular data across genomic platforms

4 Feb 2022 | bioRxiv
Belleau, Pascal, Deschênes, Astrid, Tuveson, David, Krasnitz, Alexander

See more publications